Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
33 Pages - GLDATA55963
$250.00

Summary

Selexis SA (Selexis) is a biotechnology company that develops technologies for drug discovery, cell line development and manufacture of biopharmaceutical products. The company by utilizing its technology platform develops a pipeline of technologies such as Selexis Genetic Elements, Selexis SUREtech Vectors, Selexis SUREfection Procedures, Selexis SURE CHO-M Cell Line and Selexis SURE CHO-Mplus Libraries are among others. It offers services such as cell line development, lead identification, genome characterization, MAb humanization and licensing. Selexis caters products and services to bioproduction, biopharmaceuticals, biotechnology, contract manufacturing, clinical research, diagnostics, pharmaceutical, vaccines and other industries. Selexis is headquartered in Geneva, Switzerland.

Selexis SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Selexis SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Selexis SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Selexis SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Selexis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Selexis SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Selexis SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Complix Partners with Selexis 10
Faron Pharma Enters into Agreement with Selexis 11
JHL Biotech Enters Into Agreement With Selexis For Drug Development 12
Selexis Enters Into Partnership Agreement With Fusion Antibodies 13
Oncobiologics Enters into Research Agreement with Selexis 14
BIOCRATES Life Sciences Enters Into Co-Development Agreement With Selexis 15
Laureate Pharma Enters Into An Agreement With Selexis 16
Licensing Agreements 17
Opthea Enters Into Licensing Agreement With Selexis For Wet AMD Product 17
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1045 18
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1050 20
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-3010 21
Selexis Expands License Agreement With Amgen 23
Selexis Enters Into Licensing Agreement With CSL 24
Selexis Enters Into Licensing Agreement With Neogenix Oncology 25
Asset Transactions 26
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 26
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 27
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 28
Selexis SA - Key Competitors 30
Kesy Employees 31
Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Selexis SA, Pharmaceuticals & Healthcare, Key Facts 1
Selexis SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Selexis SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Selexis SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Selexis SA, Deals By Therapy Area, 2010 to YTD 2016 8
Selexis SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Complix Partners with Selexis 10
Faron Pharma Enters into Agreement with Selexis 11
JHL Biotech Enters Into Agreement With Selexis For Drug Development 12
Selexis Enters Into Partnership Agreement With Fusion Antibodies 13
Oncobiologics Enters into Research Agreement with Selexis 14
BIOCRATES Life Sciences Enters Into Co-Development Agreement With Selexis 15
Laureate Pharma Enters Into An Agreement With Selexis 16
Opthea Enters Into Licensing Agreement With Selexis For Wet AMD Product 17
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1045 18
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1050 20
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-3010 21
Selexis Expands License Agreement With Amgen 23
Selexis Enters Into Licensing Agreement With CSL 24
Selexis Enters Into Licensing Agreement With Neogenix Oncology 25
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 26
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 27
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 28
Selexis SA, Key Competitors 30
Selexis SA, Key Employees 31
Selexis SA, Subsidiaries 32

List of Figures
Selexis SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Selexis SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Selexis SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Selexis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Selexis SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Selexis SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Selexis SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Selexis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838